CODX (Co-Diagnostics Inc) Return on Sales by Gross Profit

CODX (Co-Diagnostics Corp) - company brandmark

Leveraging its status as a technological pioneer in PCR testing, Co-Diagnostics, Inc. (CODX) is expanding global infection monitoring. The adjusted gross margin clearly illustrates the efficiency of available rapid diagnostic methods, while -149.30 shows the value of this parameter. Despite steady sales of Logix Smart systems, the pandemic-era windfall momentum has faded, leaving behind moderate operational tone.

Co-Diagnostics, Inc. (CODX) Gross Margin: for the period 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company Co-Diagnostics Inc (CODX)

- business market valuation indicators:
Basic company analysis:CODX - Co-Diagnostics Corp
Brand item of Co-Diagnostics

Gross margin determines the portion of revenue remaining after covering direct production costs, allowing investors to assess the efficiency of cost-of-goods-sold management. An analysis of the gross margin ratio demonstrates the ability of Co-Diagnostics, Inc. (CODX) to monetize the CoPrime platform patents, where high profitability is sustained by stringent FDA and CLIA regulatory barriers that limit competition within the PCR testing segment.